Literature DB >> 16175200

Antigenic and genetic characterization of serogroup C meningococci isolated from invasive meningococcal disease cases in Canada from 1999 to 2003.

Dennis K S Law1, Jan Stoltz, Averil M Henderson, Raymond S W Tsang.   

Abstract

Four hundred and forty-two serogroup C Neisseria meningitidis isolates from individual invasive meningococcal disease (IMD) patients in Canada during the period 1999 to 2003 were analyzed. The majority (84%) of the serogroup C meningococci were characterized by the serotype antigen 2a and belonged to the clonal complex of electrophoretic type ET-15. However, after more than a decade of endemic disease as well as a number of outbreaks and many vaccination campaigns, both genetic and antigenic variants of the serogroup C serotype 2a meningococci were noted. Such variants include strains characterized as C:2a:P1.5 and C:2a:P1.7,1 as well as a non-serotypeable phenotype due to a mutational hot spot on the serotype 2a PorB outer-membrane protein. Meningococci characterized by the antigen formula B:2a:P1.5,2 and B:2a:P1.7,1 have also been found, which suggests capsule switching. Besides the clonal group of ET-15/ET-37, small numbers of serogroup C isolates were found to belong to the clonal complexes of ST-8 (Cluster A4), ST-41/44 (Lineage 3), ST-35, and ST-269.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175200     DOI: 10.1139/w05-085

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  6 in total

1.  Genetic and antigenic analysis of invasive serogroup C Neisseria meningitidis in Canada: A decrease in the electrophoretic type (ET)-15 clonal type and an increase in the proportion of isolates belonging to the ET-37 (but not ET-15) clonal type during the period from 2002 to 2009.

Authors:  Jianwei Zhou; Frances Jamieson; Sharon Dolman; Linda Mn Hoang; Prasad Rawte; Raymond Sw Tsang
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Authors:  Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

Review 4.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

5.  Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011.

Authors:  Y A Li; R Tsang; S Desai; H Deehan
Journal:  Can Commun Dis Rep       Date:  2014-05-01

6.  The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Authors:  Rodica Gilca; Geneviève Deceuninck; Brigitte Lefebvre; Raymond Tsang; Rachid Amini; Vladimir Gilca; Monique Douville-Fradet; France Markowski; Philippe De Wals
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.